LSV Asset Management Has $405.41 Million Stock Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

LSV Asset Management grew its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 3,542,898 shares of the biopharmaceutical company’s stock after purchasing an additional 43,464 shares during the quarter. Alexion Pharmaceuticals makes up 0.8% of LSV Asset Management’s holdings, making the stock its 24th largest holding. LSV Asset Management’s holdings in Alexion Pharmaceuticals were worth $405,413,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Maverick Capital Ltd. bought a new position in Alexion Pharmaceuticals in the first quarter valued at approximately $190,000. APG Asset Management N.V. boosted its holdings in shares of Alexion Pharmaceuticals by 185.9% in the 1st quarter. APG Asset Management N.V. now owns 132,904 shares of the biopharmaceutical company’s stock valued at $11,933,000 after buying an additional 86,412 shares during the last quarter. Colony Group LLC bought a new position in shares of Alexion Pharmaceuticals in the first quarter valued at $338,000. FDx Advisors Inc. increased its holdings in Alexion Pharmaceuticals by 52.2% during the first quarter. FDx Advisors Inc. now owns 3,055 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 1,048 shares during the last quarter. Finally, Verus Capital Partners LLC raised its position in Alexion Pharmaceuticals by 560.0% during the first quarter. Verus Capital Partners LLC now owns 660 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 560 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Alexion Pharmaceuticals stock traded down $1.93 during trading hours on Monday, reaching $119.68. 20,336 shares of the stock were exchanged, compared to its average volume of 2,373,898. The company has a current ratio of 4.79, a quick ratio of 4.28 and a debt-to-equity ratio of 0.22. Alexion Pharmaceuticals, Inc. has a twelve month low of $72.67 and a twelve month high of $128.57. The company has a market cap of $26.65 billion, a P/E ratio of 11.11, a price-to-earnings-growth ratio of 1.02 and a beta of 1.35. The stock has a 50 day moving average of $115.69 and a two-hundred day moving average of $108.81.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $3.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.79. Alexion Pharmaceuticals had a net margin of 15.28% and a return on equity of 22.57%. The business had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.27 billion. On average, analysts expect that Alexion Pharmaceuticals, Inc. will post 10.2 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on the stock. ValuEngine lowered shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 28th. William Blair reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, October 7th. SVB Leerink upped their price objective on shares of Alexion Pharmaceuticals from $159.00 to $163.00 and gave the company an “outperform” rating in a report on Friday, July 31st. TheStreet lowered shares of Alexion Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, July 30th. Finally, Stifel Nicolaus cut their target price on shares of Alexion Pharmaceuticals from $120.00 to $117.00 and set a “hold” rating for the company in a research note on Tuesday, September 1st. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $140.35.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Featured Article: What is an investor looking for in an SEC filing?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.